Ads
related to: Renal Cell Carcinoma
Search results
Multiphase comparative study for WHO/ISUP nuclear grading diagnostic model based on enhanced CT...
Nature· 3 days agoTo compare and analyze the diagnostic value of different enhancement stages in distinguishing low and high nuclear grade clear cell renal cell ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga via Yahoo Finance· 2 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Galvanize Therapeutics' endoscopic, pulsed-field needle scores FDA clearance in cancer, soft tissue...
FierceBiotech· 2 days agoPulsed field ablation has been making waves in cardiac procedures in the past few months following a...
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL) By GuruFocus
Investing.com· 7 days agoFollowing this transaction, the insider now owns 5,445 shares of Exelixis Inc. Exelixis Inc is a...
Factor Bioscience Successfully Defends Three U.S. Patents Covering Foundational Methods for...
KOLR - KSFX Ozarks· 2 days ago-Patented methods relate to multiple allogeneic CAR T-cell therapies under clinical development for the treatment of B-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, and < ...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 6 days agoAccording to the results, 16.7% of response-evaluable patients experienced clinical benefits from...
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
Zacks via Yahoo Finance· 2 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
Clinical-stage cancer biotech Actuate latest to eye summer IPO
FierceBiotech· 2 days agoCould the IPO window really be reopening for the summer? The second biotech proposition in May seems...
Merck stock climbs as breast cancer Phase 3 trial data meets endpoint By Investing.com
Investing.com· 2 days agoMerck & Co (MRK) announced on Tuesday that its phase 3 KEYNOTE-522 trial evaluating Keytuda...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
NBC 10 - FOX 14 Monroe· 7 days agoOn May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal